RIKER LAUREN sold $144K of PCRX
RIKER LAUREN (Senior Vice President, Finance) sold 6,115 shares of Pacira BioSciences, Inc. (PCRX) at $23.50 ($0.14M total) on 2026-06-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price ($23.50), and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment monitoring, but there is no fundamental catalyst in the text.
What to watch
10b5-1 plans can be scheduled for liquidity/tax needs; without context on prior sales frequency, the signal is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for Pacira BioSciences.
Ticker impact
Pacira BioSciences insider (SVP Finance) sold 6,115 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low near-term impact; any effect is likely noise unless follow-on insider activity or fundamentals change.
The filing is a standard officer sale with a stated 10b5-1 plan and no accompanying operational/regulatory catalyst in the text.
Market effects
No sector read-through; this is company-specific insider transaction disclosure only.
None indicated.
None indicated.
Counterpoint
A cluster of insider sales (not shown here) could still indicate reduced confidence, even if executed under 10b5-1.
Key entities
- issuerPacira BioSciences, Inc.
Subject of the Form 4 insider transaction disclosure (PCRX).
- insiderRIKER LAUREN
Senior Vice President, Finance who sold 6,115 shares on 2026-06-11 under a 10b5-1 plan.
